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Background: Single-dose azithromycin is recommended over multi-dose doxycycline as treatment for chlamydial
infection. However, even with imperfect adherence, doxycycline is more effective in treating genital and rectal
infection. Recently, it has been suggested that autoinoculation from the rectum to the genitals may be a source of
persistent chlamydial infection in women. We estimated the impact autoinoculation may have on azithromycin and
doxycycline effectiveness.
Methods: We estimate treatment effectiveness using a simple mathematical model, incorporating data on
azithromycin and doxycycline efficacy from recent meta-analyses, and data on prevalence of rectal infection in
women with genital chlamydial infection.
Results: When the possibility of autoinoculation is taken into account, we calculate that doxycycline effectiveness
may be 97% compared to just 82% for azithromycin.
Conclusions: Consideration should be given to re-evaluating azithromycin as the standard treatment for genital
chlamydia in women.
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Single-dose azithromycin has been recommended over a
week-long doxycycline course as treatment for genital
chlamydial infection, primarily because of concern about
lack of adherence for the longer doxycycline course.
However, the assumed superiority of azithromycin has
been questioned [1]. In 2002, a meta-analysis concluded
that azithromycin and doxycycline were equally effica-
cious in treating urogenital chlamydial infection (with ef-
ficacies of 97% and 98% respectively) [2], but a 2014
meta-analysis found a greater disparity, with efficacies of* Correspondence: bdonovan@kirby.unsw.edu.au
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unless otherwise stated.94.3% for azithromycin and 97.1% for doxycycline [3]. For
rectal infection, the difference may be greater: another sys-
tematic review estimated treatment efficacies of 82.9% for
azithromycin and 99.6% for doxycycline [4], with different
delivery mechanisms being suggested as a possible reason
for the difference [5]. Additionally, background use of
tetracyclines but not macrolides has been found to be
associated with lower chlamydia prevalence [6].
It has recently been proposed that autoinoculation
(the inoculation of a site with infective bodies from an-
other site on the same individual) of chlamydia from the
gastrointestinal (GI) tract to the genital tract is possible in
women, and that the GI tract may be a niche for persistent
infection [7-9]. Mice orally infected with chlamydia de-
velop genital infections [10], similar to Escherichia colihis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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faecal contamination, and rectal-vaginal autoinoculation is
suspected to occur in infants [11]. It is at least theoreti-
cally possible, if not likely, that chlamydiae in the GI tract
that have survived treatment with antibiotics may re-
infect the genital tract in humans. Persistent infection or
repeat infections in women are very common, with esti-
mates of up to 29.9% among women reported [12], and
are of concern because of the increased risk of pelvic
inflammatory disease with repeat infection. If there is a
substantial difference in the efficacy of doxycycline and
azithromycin in resolving GI/rectal infection, and autoino-
culation is a possibility, this may be further cause for
reconsidering azithromycin as the preferred treatment for
genital chlamydial infection.
We perform a simple calculation to estimate the prob-
ability that a woman with a genital chlamydial infection,
treated with either azithromycin or doxycycline, remains
chlamydia-free when the possibility of autoinoculation is
considered. At present there are no estimates of the
probability of autoinoculation from rectum to genital
tract, so we consider the full range of probabilities from
zero (autoinoculation never occurs) to one (autoinocula-
tion always occurs). We consider two scenarios: the case
of a woman known to be genitally infected but who has
not been tested for rectal infection (as is usual practice),
and the case of a woman known to have both genital
and rectal infection.Figure 1 Chance of remaining chlamydia-free in genital tract after
treatment. It is assumed that no rectal swab has been taken. The
ranges reflect the range of probabilities for autoinoculation.Methods
We use the random effects estimates of the efficacy of
azithromycin and doxycycline from two recent sys-
tematic reviews: 94.3% for azithromycin and 97.1% for
doxycycline against genital chlamydial infection [3], and
82.9% for azithromycin and 99.6% for doxycycline
against rectal infection [4]. A subgroup analysis of just
those studies that did not measure doxycycline compli-
ance (and that therefore did not exclude any subjects
based on low compliance levels) found a very similar
random effects pooled estimate for difference in treat-
ment efficacy to the estimate when all studies were in-
cluded (1.4% and 1.5% respectively) [3], suggesting that
these values are sufficiently close to real-world ‘use-
effectiveness’ for the purposes of our study.
When women with genital chlamydial infection are
tested for rectal infection, around 71-89% are positive
[13-16]. Notably, there was no association with anal
intercourse in those studies that reported it [14-16]. We
assume 77% as the mean of the studies’ estimates. For
the purposes of this study, we assume that the proba-
bility of genital infection cure, the probability of gastro-
intestinal tract infection cure, and the probability of
autoinoculation are all independent.If no rectal swab is taken, the probability that a
woman remains free of genital infection after treatment
can be estimated based on the probabilities of resolving
genital and rectal infections and the probability of autoi-
noculation from the rectum to genitals; mathematically,
the probability can be denoted by the expression:
Pgenital 1− 1−Prectalð ÞPautoinoculationPpositive
 
;
where Pgenital is the probability that a genital infection is
resolved by treatment, Prectal is the probability that a rec-
tal infection is resolved by treatment, Pautoinoculation is
the probability of autoinoculation occurring in a woman
with a rectal infection, and Ppositive is the probability of a
woman with a genital infection also having a rectal in-
fection. If the woman is known to have a rectal infection,
the probability of remaining free of genital infection can
be expressed mathematically as:
Pgenital 1− 1−Prectalð ÞPautoinoculation½ :
Results and discussion
In Figure 1, we show the chance of the woman re-
maining free of genital chlamydial infection after treat-
ment with either azithromycin or doxycycline, assuming
that a rectal swab was not taken. The ranges reflect the
autoinoculation probability varying from zero to one.
When the probability of autoinoculation is one, the
chance of the patient remaining free of genital infection
after treatment with doxycycline is 96.8%, and 81.9% for
azithromycin. That is, a 3.2% and 18.1% chance, respec-
tively, of not clearing the infection. This corresponds to
a 5.7-fold greater chance of not clearing an infection
with azithromycin compared with doxycycline.
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fore treatment (i.e., if a positive rectal swab had been
taken) then the ranges become wider: the chance of
remaining free of genital infection after treatment with
azithromycin is 78.2-94.3%, and after treatment with
doxycycline 96.7-97.1%. This corresponds to a 2.0-6.6-
fold greater chance of not clearing a chlamydial infection
with azithromycin compared with doxycycline.
Using estimates from the literature of the efficacy of
azithromycin and doxycycline in treating genital and rec-
tal chlamydial infections, along with some simple as-
sumptions, we have obtained estimates of the percentage
chance of remaining free of chlamydia after treatment
for genital chlamydia when the possibility of autoinocu-
lation from rectum to genitals is taken into account. If
autoinoculation does not occur, the efficacies of azithro-
mycin and doxycycline are as reported in the systematic
review (94.3% for azithromycin and 97.1% for doxycyc-
line) and there is approximately a 2-fold greater chance
of not clearing the infection with azithromycin. If autoi-
noculation has a high probability of occurring, then the
efficacy of azithromycin may be as low as 81.9% when a
patient’s rectal infection status is unknown, and as low
as 78.2% if the patient is known before treatment to have
a rectal infection. This means that the chance of not
clearing an infection could be 6 times greater with azi-
thromycin compared with doxycycline. It has usually
been assumed that new infections detected after treat-
ment for genital infection are due to re-infection by a
partner, but it may be that some are due to autoinocula-
tion. The disparity in efficacies provides further support
for the careful re-evaluation of azithromycin as the pre-
ferred treatment for chlamydia.
Measuring the probability that autoinoculation from
rectum to genitals occurs would be difficult. Assuming
that there is some daily chance that autoinoculation oc-
curs, whether autoinoculation has taken place would be
a function of time since treatment. However, this is also
the case for re-infection from a partner, and it would be
difficult to separate the effects of these two mechanisms
of re-infection. We recommend post-treatment tests for
re-infection at both genital and rectal sites, as this will of
course capture re-infection regardless of its source.
The ‘use-effectiveness’ of doxycycline does seem to
be high, with a study that monitored adherence using
microchipped medication bottles finding that chlamydial
infection resolved in 76 of 81 (93.8%) of patients [17].
However, adherence did have an impact, with all 4 of the
patients who failed therapy and were evaluable (i.e.,
returned their medication bottles) having at least two
24-hour intervals during which they did not take medi-
cation. Additionally, none of the evaluable 58 patients
who took at least 10 doses failed therapy, while 4 of the
evaluable 20 patients who took less than 10 doses failedtherapy. While it seems that good use-effectiveness can
be had from doxycycline, excessively low adherence is
clearly to be avoided. Providers proscribing doxycycline
for treatment of urogenital chlamydia should continue
to encourage patients to take their full courses of
medication.
Conclusions
We have generated estimates of the percentage chance
of a woman treated for genital chlamydia remaining free
of genital infection after treatment, and found that this
is much lower for azithromycin when autoinoculation
from the rectum to the genitals is likely. A return to
doxycycline as the standard treatment for chlamydial
infection should be considered, and treatment trials of
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